PMID- 16334021
OWN - NLM
STAT- MEDLINE
DCOM- 20060112
LR  - 20191210
IS  - 0001-5547 (Print)
IS  - 0001-5547 (Linking)
VI  - 49
IP  - 5
DP  - 2005 Sep-Oct
TI  - Fluorescence in situ hybridization for HER-2/neu amplification of breast 
      carcinoma in archival fine needle aspiration biopsy specimens.
PG  - 471-6
AB  - OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) 
      for HER-2/neu amplification of breast carcinoma in archival fine needle 
      aspiration biopsy (FNAB) specimens. STUDY DESIGN: All FISH performed on 
      formalin-fixed, paraffin-embedded surgical specimens during January 2003-August 
      2003 at the University of California Irvine Medical Center were selected. Prior 
      FNABs were retrieved. One cytologic slide was destained in each case. The results 
      were compared with those obtained on histologic specimens using the paired t 
      test. RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma. 
      Thirteen patients had prior FNABs that were positive for adenocarcinoma. After 
      hybridization on destained fine needle aspiration slides, no cells were found in 
      2 cases, and the results were not readable in 2 cases. In the remaining 9 cases, 
      the results, expressed as the ratio of copies of the HER-2/neu gene to copies of 
      the chromosome 17 centromere, were 5.10, 1.14, 1.21, 1.12, 0.74, 1.11, 1.21, 9.87 
      and 2.4. Results on the corresponding histologic specimens were 5.25, 1.05, 1.13, 
      1.22, 1.13, 1.12, 1.21, 9.35 and 2.61, respectively. No significant difference 
      was found (p = 0.23). CONCLUSION: HER-2/neu amplification status by FISH can be 
      accurately and reliably evaluated in existing archival cytologic slides.
FAU - Gu, Mai
AU  - Gu M
AD  - Department of Pathology, University of California Irvine Medical Center, Orange, 
      California 92868, USA. mgu@uci.edu
FAU - Ghafari, Sophie
AU  - Ghafari S
FAU - Zhao, Manxu
AU  - Zhao M
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - Switzerland
TA  - Acta Cytol
JT  - Acta cytologica
JID - 0370307
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Archives
MH  - Biopsy, Fine-Needle
MH  - Breast Neoplasms/*diagnosis/genetics/metabolism
MH  - Carcinoma/*diagnosis/genetics/metabolism
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Female
MH  - Gene Amplification/*genetics
MH  - Gene Dosage/genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry/methods/trends
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Trastuzumab
EDAT- 2005/12/13 09:00
MHDA- 2006/01/13 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/01/13 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
AID - 10.1159/000326190 [doi]
PST - ppublish
SO  - Acta Cytol. 2005 Sep-Oct;49(5):471-6. doi: 10.1159/000326190.